Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma.

Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma.

Sorafenib (SOR) is the only systemic agent known to improve survival for hepatocellular carcinoma (HCC). However, SOR prolongs survival by less than 3 months and does not alter symptomatic progression. To improve outcomes, several phase I-II trials are currently examining SOR with radiation (RT) for...

Full description

Bibliographic Details
Main Authors: Aaron T Wild, Nishant Gandhi, Sivarajan T Chettiar, Khaled Aziz, Rajendra P Gajula, Russell D Williams, Rachit Kumar, Kekoa Taparra, Jing Zeng, Jessica A Cades, Esteban Velarde, Siddharth Menon, Jean F Geschwind, David Cosgrove, Timothy M Pawlik, Anirban Maitra, John Wong, Russell K Hales, Michael S Torbenson, Joseph M Herman, Phuoc T Tran
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3675179?pdf=render

Internet

http://europepmc.org/articles/PMC3675179?pdf=render

Similar Items